HuidaGene Therapeutics to Present at Multiple Key Conferences Highlighting Advances in CRISPR-based Therapies

SHANGHAI and MIDDLETOWN (DE), March 03, 2025—HuidaGene Therapeutics (“HuidaGene”), a global clinical-stage biotechnology company pioneering next-generation genome medicines, today announced its participation in multiple upcoming conferences. HuidaGene will present advancements in CRISPR-based gene-editing and RNA-targeting therapies at these conferences. HuidaGene’s presentations will showcase the latest progress in AI-driven CRISPR engineering, DNA editing for Duchenne muscular dystrophy (DMD), and RNA-targeting approaches for age-related macular degeneration (AMD).

Upcoming presentations:

• University College Cork School of Biochemistry and Cell Biology Seminar

o Date: March 3, 2025

o Location: Cork, Ireland

o Presentation: AI-driven HG-PRECISE engineering of hfCas12Max for pre-clinical DMD studies supporting the M.U.S.C.L.E. trial

o Time: 11:00 AM, Brookfield Health Sciences Complex (BHSC) G06.

• Keystone Symposia-Precision Genome Engineering: Translating the Human Genome to the Clinic

o Date: March 3-6, 2025

o Location: Killarney, Ireland

o Presentation: CRISPR/hfCas12Max DNA-editing restores muscle function in Duchenne muscular dystrophy: from bench to bedside

o Time: 3:00-4:30 PM, INEC Main Auditorium

• 5^th Annual Wet AMD & Diabetic Eye Disease Drug Summit

o Date: March 18-20, 2025

o Location: Boston, MA, USA

oPresentation: In-vitro and in-vivo studies to support the world's first CRISPR/RNA-targeting therapy, HG202, for patients with neovascular age-related macular degeneration

o Venue: Hilton Boston Back Bay

“We are excited to showcase our AI-driven advancements in CRISPR-based gene editing,” TJ Cradick, Ph.D., Chief Technology Officer at HuidaGene, emphasized the importance of these upcoming presentations. “Our work on hfCas12Max is setting new standards in precision and efficiency, particularly in addressing DMD and other genetic diseases. These conferences allow us to share our innovations and data with the global scientific community and advance discussions on next-generation genome medicines.”

Alvin Luk, Ph.D., M.B.A., C.C.R.A., CEO and Co-founder of HuidaGene, highlighted the company's commitment to delivering transformative therapies: “At HuidaGene, we are dedicated to developing safer, more effective gene-editing and RNA-targeting therapies to address severe genetic disorders. Our AI-driven HG-PRECISE^Ò platform has enabled us to build a comprehensive gene-editing toolbox with highly optimized nucleases, expanding our capabilities beyond traditional CRISPR approaches. This allows us to precisely tailor gene-editing strategies for different diseases, including DMD and AMD. Our participation in these conferences reflects our leadership in pioneering CRISPR innovations that can potentially change patients' lives. We look forward to engaging with fellow researchers and industry leaders as we continue to push the boundaries of genetic medicine.”

About HuidaGene

HuidaGene utilizes its proprietary AI-driven, CRISPR-based HG-PRECISE^Ò platform to develop potentially curative genome medicine. The Company is advancing clinical programs, including trials of HG004 (granted ODD & RPDD by FDA) 'LIGHT' trial (NCT06088992) and Phase 1/2 international, master-protocol 'STAR' clinical trial (NCT05906953) in RPE65-associated retinal disease, HG202 RNA-editing therapy 'SIGHT-I' first-in-human trial (NCT06031727) and 'BRIGHT' Phase 1 clinical trial (NCT06623279) for nAMD, HG204 RNA-editing therapy (granted ODD & RPDD by FDA and ODD by EMA) 'HERO' trial (NCT06615206) for MECP2 duplication syndrome, and HG302 DNA-editing therapy (granted ODD & RPDD by FDA) first-in-human 'MUSCLE' trial (NCT06594094) for DMD. The preclinical programs include HG303 DNA-editing for ALS and CRISPR RNA-editing therapy for Alzheimer's and Huntington's Disease. With an extensive intellectual property portfolio, HuidaGene is a leader in genome medicines for neurology and ophthalmology. Learn more at huidagene.com or on LinkedIn.